Compare YAAS & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YAAS | LYRA |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.4M |
| IPO Year | 2024 | 2020 |
| Metric | YAAS | LYRA |
|---|---|---|
| Price | $1.61 | $3.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 163.4K | 36.5K |
| Earning Date | 02-15-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $581,862.00 | ★ $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.30 | $2.84 |
| 52 Week High | $560.00 | $37.50 |
| Indicator | YAAS | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 29.22 |
| Support Level | $1.58 | $3.19 |
| Resistance Level | $1.73 | $3.70 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 39.02 | 1.51 |
Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses to develop, use and control business applications without the need to purchase complex IT infrastructure. The company leverages the technologies used to develop its PaaS platform to standardize customized customer relationship management, or CRM, services to its clients that seamlessly connect all levels of the retail chain from management teams to customers. Its products give its retail clients a comprehensive view of their business operations in real-time on multiple interfaces, allowing them to make critical business decisions anytime and anywhere. Geographically operates in PRC, Hong Kong, and Cayman Island.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.